Evive Biotech meets primary and secondary endpoints in global Phase III clinical trial for their novel chemotherapy-induced neutropenia treatment
- Category: Proteins and Peptides
- Published on Wednesday, 08 July 2020 10:49
- Hits: 1595
- Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF
- Key milestone and validation for Evive's novel biologic development capability and technology platform
- Key component of the asset's BLA submission to receive regulatory approval from the FDA
- Completes robust development program involving 10 successful clinical trials with over 1,200 subjects
SHANGHAI, China I July 7, 2020 I Evive Biotech, a global biologics company developing novel biological therapies, is delighted to announce that its pivotal Phase III study (NCT03252431) for F-627 (efbemalenograstim alpha) to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints, demonstrating strong and lasting benefit.
F-627 increases the production of white blood cells (neutrophils) which are a key part of the immune system's ability to fight infection. A low concentration of these cells is a common side-effect of chemotherapy, and boosting their levels strengthens the immune system, meaning that patients are less likely to succumb to infections during treatment with chemotherapy.
"F-627 has now shown positive results in its pivotal Phase III trial. We are excited that this trial has met its efficacy and safety endpoints as we believe that it has the potential to positively impact cancer treatment," said Dr. William Daley, Evive's Chief Medical Officer. "F-627 has proven that it is at least as efficacious and safe as NEULASTA®, which is the current standard of care. This successful trial result reinforces F-627's potential to be a strong first line treatment, and an alternative for patients contraindicated or refractory to current treatment options. F-627's fusion protein structure presents a unique alternative as it reduces the possibility of allergic reactions caused by PEGylation used in pegfilgrastim. It was also very encouraging to see that the treatment was well tolerated, with infection rates for those treated with F-627 lower than in the control arm of the trial which was more pronounced in certain patient subgroups."
"The successful completion of our global Phase III trial for F-627 is a validation of Evive's platform, and the entire team's commitment, dedication and belief in this product," said Jacky Liu, CEO of Evive. "This moment is a key milestone for us as a business as we move towards submitting F-627's BLA application to the FDA -- one of the first Asian biologics companies to advance a novel biologic product from pre-clinical studies to BLA submission. As we begin the next stage of our journey, exploring commercialization partnerships to make this product available to patients worldwide, I would like to thank the Evive team, trial clinics and doctors who have worked so tirelessly to develop this critical and potentially life-saving treatment."
The global pivotal Phase III trial was a multi-center, randomized, single dose, double-blind, active-controlled study comparing the efficacy and safety of Evive's F-627 (dimeric recombinant human granulocyte colony stimulating factor-fc fusion protein) and Neulasta® (pegylated recombinant methionyl human granulocyte colony stimulating factor) in the prophylactic treatment of chemotherapy-induced neutropenia in women with breast cancer receiving myelotoxic TC chemotherapy treatment (docetaxel + cyclophosphamide).
This trial was conducted under a Special Protocol Assessment (SPA) in agreement with the Food and Drug Administration (FDA) of the United States Federal Government and will be submitted as part of the Biologic License Application (BLA) filing to the FDA, and the Market Authorization Application (MAA) filing to the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). F-627's global development program also includes successfully completed placebo-controlled and Neupogen-controlled Phase III trials that met all primary and secondary endpoints. In total, the program involved 10 trials and over 1,200 subjects.
As Evive progresses its BLA submission with the FDA and equivalent submissions around the world, it is exploring commercialization partnerships for F-627 in the US, Europe, Japan and China, as well as Rest of World countries to ensure the broadest access for patients around the globe.
Notes for Editors
Chemotherapy-induced Neutropenia (CIN)
CIN occurs commonly during current cancer treatments involving cytotoxic chemotherapy. Market research indicates that CIN affects more than eight million people every year with around one million people affected in the United States alone. The global CIN market is estimated to be at US$6.0 billion with about >85% of patients still on first-generation of rhG-CSFs, and less than 15% of patients using second-generation rhG-CSFs, the pegylated rhG-CSF.
F-627 (efbemalenograstim alpha) is under development for the treatment of CIN in cancer patients after chemotherapy. F-627 is a recombinant fusion protein containing G-CSF at the amino terminal and human IgG2-Fc fragment at the carboxyl terminal. F-627 is expressed in Chinese Hamster Ovary (CHO) cells. F-627 exists as a dimer with two molecules of rhG-CSF covalently linked through disulfide bonds formed between the Fc fragment of the molecule. G-CSF is a growth factor acting on the neutrophilic lineage in the hematopoietic system. G-CSF binds specifically to G-CSF receptors (G-CSFR) on precursor cells in bone marrow and mature neutrophils. G-CSF stimulates survival, proliferation, differentiation, function of neutrophil precursors and mature neutrophils.
About Evive Biotech
Evive Biotech is a global biologics company with Asian roots, developing a portfolio of novel biological therapies for patients and healthcare professionals worldwide. We leverage our two proprietary technology platforms, DiKine™ and ITab™, to advance a series of innovative drug candidates for oncology and inflammatory disorders. Founded in 2004, we have over 200 employees today with operations in the US, Singapore and China. We adopt a holistic approach to drug development, combining exceptional research and commercialization capabilities with world class in-house regulatory expertise to bring innovative therapies to market quickly and efficiently. To learn more, visit www.evivebiotech.com.
Evive Biotech is the new name for Generon Biomed.
SOURCE: Evive Biotech